CM
Castleark Management Portfolio holdings
AUM
$3.33B
This Quarter Return
-12.72%
1 Year Return
+37.9%
3 Year Return
+222.09%
5 Year Return
+481.09%
10 Year Return
+2,703.89%
AUM
$1.69B
AUM Growth
+$1.69B
(-32%)
Cap. Flow
-$417M
Cap. Flow
% of AUM
-24.67%
Top 10 Holdings %
Top 10 Hldgs %
25.69%
Holding
412
New
71
Increased
67
Reduced
132
Closed
76
Top Buys
| 1 |
SPDR Gold Trust
GLD
|
$30.2M |
| 2 |
DexCom
DXCM
|
$19M |
| 3 |
Lam Research
LRCX
|
$18.2M |
| 4 |
NVIDIA
NVDA
|
$17.7M |
| 5 |
Paycom
PAYC
|
$15.7M |
Top Sells
| 1 |
iShares 20+ Year Treasury Bond ETF
TLT
|
$57.1M |
| 2 |
Match Group
MTCH
|
$23.7M |
| 3 |
CDW
CDW
|
$23M |
| 4 |
VanEck Semiconductor ETF
SMH
|
$22.7M |
| 5 |
Nike
NKE
|
$22.2M |
Sector Composition
| 1 | Technology | 35.02% |
| 2 | Healthcare | 19.23% |
| 3 | Consumer Discretionary | 13.37% |
| 4 | Financials | 9.72% |
| 5 | Industrials | 9.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Neurocrine Biosciences
NBIX
$13.6B
| $5.02M | 0.3% |
57,972
-35,995
| -38% | -$3.12M |
|
102
MACOM Technology Solutions
MTSI
$9.55B
| $4.95M | 0.29% |
261,637
+69,180
| +36% | +$1.31M |
|
|
TPTX
103
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $4.91M | 0.29% |
110,017
+44,055
| +67% | +$1.97M |
|
|
RCM
104
DELISTED
R1 RCM Inc. Common Stock
RCM
| $4.85M | 0.29% |
533,859
+50,700
| +10% | +$461K |
|
|
MODN
105
DELISTED
MODEL N, INC.
MODN
| $4.73M | 0.28% |
212,861
+83,064
| +64% | +$1.84M |
|
106
Bandwidth Inc
BAND
$460M
| $4.57M | 0.27% |
+67,927
| New | +$4.57M |
|
|
EVBG
107
DELISTED
Everbridge, Inc. Common Stock
EVBG
| $4.47M | 0.26% |
+41,995
| New | +$4.47M |
|
108
OneMain Financial
OMF
$7.28B
| $4.46M | 0.26% |
233,117
-6,455
| -3% | -$123K |
|
109
Tower Semiconductor
TSEM
$6.92B
| $4.45M | 0.26% |
279,590
+11,510
| +4% | +$183K |
|
110
Crown Holdings
CCK
$10.7B
| $4.44M | 0.26% |
76,410
-23,744
| -24% | -$1.38M |
|
111
Visteon
VC
$3.39B
| $4.37M | 0.26% |
91,010
-3,030
| -3% | -$145K |
|
112
Pinnacle Financial Partners
PNFP
$7.5B
| $4.35M | 0.26% |
115,775
+4,760
| +4% | +$179K |
|
|
MYOK
113
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $4.29M | 0.25% |
91,606
-24,305
| -21% | -$1.14M |
|
114
Stifel
SF
$11.5B
| $4.25M | 0.25% |
102,975
+38,035
| +59% | +$1.57M |
|
|
GBT
115
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $4.25M | 0.25% |
83,105
+55,725
| +204% | +$2.85M |
|
116
Penumbra
PEN
$10.5B
| $4.16M | 0.25% |
+25,792
| New | +$4.16M |
|
|
SHYF
117
DELISTED
The Shyft Group
SHYF
| $4.15M | 0.25% |
321,135
+51,752
| +19% | +$668K |
|
118
Merit Medical Systems
MMSI
$5.29B
| $4.03M | 0.24% |
+128,820
| New | +$4.03M |
|
119
Apellis Pharmaceuticals
APLS
$3.5B
| $3.94M | 0.23% |
+147,165
| New | +$3.94M |
|
120
Flex
FLEX
$20.1B
| $3.85M | 0.23% |
+459,860
| New | +$3.85M |
|
|
RETA
121
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $3.77M | 0.22% |
+26,085
| New | +$3.77M |
|
122
LendingTree
TREE
$929M
| $3.75M | 0.22% |
+20,435
| New | +$3.75M |
|
123
Ultragenyx Pharmaceutical
RARE
$3.06B
| $3.74M | 0.22% |
+84,200
| New | +$3.74M |
|
124
Crocs
CROX
$4.93B
| $3.73M | 0.22% |
219,240
+24,095
| +12% | +$409K |
|
125
Synaptics
SYNA
$2.6B
| $3.71M | 0.22% |
+64,115
| New | +$3.71M |
|